Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

BACKGROUND: To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC). METHODS: 154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Karthaus, Meinolf, Hofheinz, Ralf-Dieter, Mineur, Laurent, Letocha, Henry, Greil, Richard, Thaler, Josef, Fernebro, Eva, Oliner, Kelly S, Boedigheimer, Michael, Twomey, Brian, Zhang, Ying, Demonty, Gaston, Köhne, Claus-Henning
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104899/
https://ncbi.nlm.nih.gov/pubmed/27764839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.343
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados